Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Increased Thromboxane in Patients with Polycythemia Vera and Thrombosis: Evidence for Aspirin-Unsuppressible Platelet Activation In Vivo

Rossella Rosari Cacciola, Elio Gentilini Cacciola, Veronica Vecchio, MDcal Student, Emma Cacciola, MD

Blood (2019) 134 (Supplement_1): 5372.

https://doi.org/10.1182/blood-2019-122828

Published: 2019

Journal Articles

Skin Blood Flow Measured By LSCI Demonstrates Treatment Effect of Chronic Transfusion Protocol in Sickle Cell Disease

Nicolas V Currier, MD PhD, Gersham Dent, PhD, Paul S. Swerdlow, MD, Willem Birkhoff, MD, Jacobus Burggraaf, MD PhD, Jaspert de Vries, Bsc, Jaladhar Neelavalli, PhD, Muhammad Shahid, MD, Brijesh K Yadav, MS, William E. Hobbs, MD PhD, Ajay Verma, MD PhD

Blood (2016) 128 (22): 4871.

https://doi.org/10.1182/blood.V128.22.4871.4871

Published: 2016

Journal Articles

CD4(+)/CD56(+) Hematodermic (plasmacytoid dendritic cell) Tumor: a Highly Proliferating Neoplasm with Aberrant Expression of Immunohistochemical Markers and Poor Outcome.

Marina Siakantaris, M.D., George Rassidakis, MD, PhD, Flora Kontopidou, MD, Aglaia Dimitrakopoulou, MD, Theodoros Vassilakopoulos, MD, Maria K. Angelopoulou, Styliani Kokkoris, MD, Nikolaos Evangelatos, MD, Konstantinos Anargyrou, MD, Othon Michail, MD, Penelope Korkolopoulou, MD, G.A. Pangalis

Blood (2009) 114 (22): 2930.

https://doi.org/10.1182/blood.V114.22.2930.2930

Published: 2009

Journal Articles

Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).

A. Pietrangelo, MD, PhD, P. Brissot, MD, H. Bonkovsky, MD, C. Niederau, L. Rojkjaer, R. Weitzman, J. Bodner, S. Bailey, Pradyumna D. Phatak, MD

Blood (2007) 110 (11): 2680.

https://doi.org/10.1182/blood.V110.11.2680.2680

Published: 2007

Journal Articles

Phase II Study To Determine If Danazol Is an Anti-D Sparing Agent When Used in Combination with Anti-D for the Treatment of Immune Thrombocytopenic Purpura.

Ibrahim N. Nakhoul, MD, Ilan Shapira, MD, May Abdo-Matkiwsky, MD, Peter Kozuch, MD, Etta Frankel, MD, Sree Bhavani Chalasani, MD, Takhir Mirzoyev, Margaret Dietrich, Peter Homel, PhD, Michael L. Grossbard, MD, Mala Varma, MD

Blood (2006) 108 (11): 3983.

https://doi.org/10.1182/blood.V108.11.3983.3983

Published: 2006

Journal Articles

Association of Low Protein Z with Ischemic Stroke in Young Women.

Mary J. Heeb, PhD, Mark Fisher, M.D., Annlia Paganini-Hill, Ph.D.

Blood (2006) 108 (11): 4107.

https://doi.org/10.1182/blood.V108.11.4107.4107

Published: 2006

Journal Articles

Correlation of Clinical and Molecular Response to Imatinib in Polycythemia Vera (PV) Patients with Bone Marrow Morphologic and Immunophenotypic Changes.

Elizabeth Hyjek, MD, PhD, Amy Chadburn, MD, Nicholas C.P. Cross, PhD, Amy V. Jones, BSc, Su-Chieh P. Sun, MS, Susan Mathew, PhD, April Chiu, MD, April Young, MS, D.M. Knowles, MD, Richard T. Silver, MD

Blood (2006) 108 (11): 4914.

https://doi.org/10.1182/blood.V108.11.4914.4914

Published: 2006

Journal Articles

Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphoctyic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.

Khuda D. Khan, MD, PhD, Susan O’Brien, MD, Kanti R. Rai, MD, Jennifer R. Brown, MD, PhD, Perry Cook, MD, Anne Marie Maddox, MD, Alison M. Duarte, MPH, Eric J. Haltom, Margaret J. Uprichard, PharmD

Blood (2005) 106 (11): 2125.

https://doi.org/10.1182/blood.V106.11.2125.2125

Published: 2005

Journal Articles

Altered Bone and Mineral Metabolism in Patients Treated with Imatinb.

Ellin Berman, MD, Maria Nicolaides, MD, Nicolas Sauter, MD, Suzanne Chanel, RN, Brianne Wilson, Martin Fleisher, PhD

Blood (2004) 104 (11): 4668.

https://doi.org/10.1182/blood.V104.11.4668.4668

Published: 2004

Journal Articles

Thalidomide for the Treatment of Low Risk Myelodysplasia.

D. Bouscary, MD-PhD, M. C. Quarre, MD, D. Vassilief, MD, O. Beyne Rouzy, MD, A. Aouba, MD, C. Berthou, MD, C. Gardembas, MD, L. Sanhes, MD, A. Guerci, MD, B. Mahe, MD, A. Stamatoullas, MD, F. Bauduer, MD, J. J. Sotto, MD, L. Legros, MD-PhD, S. Vaultier, ARC, P. Fenaux, MD-PhD, F. Dreyfus, MD

Blood (2004) 104 (11): 1438.

https://doi.org/10.1182/blood.V104.11.1438.1438

Published: 2004

NARROW

Increased Thromboxane in Patients with Polycythemia Vera and Thrombosis: Evidence for Aspirin-Unsuppressible Platelet Activation In Vivo

Skin Blood Flow Measured By LSCI Demonstrates Treatment Effect of Chronic Transfusion Protocol in Sickle Cell Disease

CD4(+)/CD56(+) Hematodermic (plasmacytoid dendritic cell) Tumor: a Highly Proliferating Neoplasm with Aberrant Expression of Immunohistochemical Markers and Poor Outcome.

Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).

Phase II Study To Determine If Danazol Is an Anti-D Sparing Agent When Used in Combination with Anti-D for the Treatment of Immune Thrombocytopenic Purpura.

Association of Low Protein Z with Ischemic Stroke in Young Women.

Correlation of Clinical and Molecular Response to Imatinib in Polycythemia Vera (PV) Patients with Bone Marrow Morphologic and Immunophenotypic Changes.

Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphoctyic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.

Altered Bone and Mineral Metabolism in Patients Treated with Imatinb.

Thalidomide for the Treatment of Low Risk Myelodysplasia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only